Larimar Historical Balance Sheet

LRMR Stock

USD 2.38 0.13 5.78%

Trend analysis of Larimar Therapeutics balance sheet accounts such as Total Current Liabilities of 12.2 M provides information on Larimar Therapeutics' total assets, liabilities, and equity, which is the actual value of Larimar Therapeutics to its prevalent stockholders. By breaking down trends over time using Larimar Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Larimar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Larimar Therapeutics is a good buy for the upcoming year.

Larimar Therapeutics Inventory

(177,840)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

About Larimar Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Larimar Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Larimar Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Larimar Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Larimar currently owns. An asset can also be divided into two categories, current and non-current.

Larimar Therapeutics Balance Sheet Chart

At this time, Larimar Therapeutics' Short Term Investments are relatively stable compared to the past year. As of 03/27/2025, Liabilities And Stockholders Equity is likely to grow to about 210.2 M, while Property Plant And Equipment Net is likely to drop slightly above 2.4 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Larimar Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Larimar Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Larimar Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Larimar Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Larimar Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Larimar Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.At this time, Larimar Therapeutics' Short Term Investments are relatively stable compared to the past year. As of 03/27/2025, Liabilities And Stockholders Equity is likely to grow to about 210.2 M, while Property Plant And Equipment Net is likely to drop slightly above 2.4 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	5.4M	5.5M	5.1M	6.9M
Total Assets	126.4M	95.9M	200.2M	210.2M

Short Long Term Debt Total Total Assets

Larimar Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Other Assets	Long Term Debt	Net Receivables
Total Assets		-0.16	0.76	0.7	0.99	0.11	-0.08	-0.58	0.25	0.07	0.08	0.51	0.99	0.51	0.84	-0.33	0.67	0.58	0.55	1.0	0.19	0.63	0.22	0.48	0.05	0.09
Short Long Term Debt Total	-0.16		-0.11	-0.11	-0.26	-0.36	0.22	-0.49	0.18	0.06	-0.38	-0.4	-0.14	-0.31	-0.16	0.57	-0.21	0.31	0.59	-0.14	0.77	-0.04	-0.32	-0.3	0.44	0.44
Other Current Liab	0.76	-0.11		0.81	0.71	0.41	0.25	-0.64	0.04	-0.28	0.38	0.81	0.7	0.87	0.77	-0.2	0.91	0.65	0.58	0.73	0.02	0.7	-0.34	0.77	0.29	-0.39
Total Current Liabilities	0.7	-0.11	0.81		0.67	0.37	0.24	-0.56	0.32	-0.23	0.32	0.53	0.67	0.6	0.73	-0.24	0.65	0.74	0.66	0.69	0.11	0.78	-0.18	0.54	0.15	-0.21
Total Stockholder Equity	0.99	-0.26	0.71	0.67		0.09	-0.11	-0.49	0.24	0.09	0.07	0.49	0.99	0.48	0.83	-0.38	0.63	0.51	0.45	0.99	0.12	0.6	0.31	0.45	-0.02	0.1
Property Plant And Equipment Net	0.11	-0.36	0.41	0.37	0.09		-0.11	-0.02	-0.32	0.02	1.0	0.67	0.02	0.63	-0.03	-0.4	0.48	0.25	0.14	0.05	-0.35	0.34	-0.65	0.55	0.1	-0.78
Net Debt	-0.08	0.22	0.25	0.24	-0.11	-0.11		-0.36	0.24	-0.96	-0.12	0.0	-0.09	0.24	0.43	0.45	0.06	0.39	0.15	-0.07	0.2	0.28	-0.37	0.4	0.46	-0.28
Retained Earnings	-0.58	-0.49	-0.64	-0.56	-0.49	-0.02	-0.36		-0.11	0.19	0.02	-0.24	-0.57	-0.39	-0.56	-0.37	-0.42	-0.91	-0.81	-0.58	-0.73	-0.65	0.26	-0.39	-0.7	-0.04
Accounts Payable	0.25	0.18	0.04	0.32	0.24	-0.32	0.24	-0.11		-0.19	-0.37	-0.4	0.28	-0.31	0.41	0.07	-0.16	0.25	0.23	0.27	0.35	-0.15	0.23	-0.33	-0.08	0.35
Cash	0.07	0.06	-0.28	-0.23	0.09	0.02	-0.96	0.19	-0.19		0.03	-0.11	0.1	-0.33	-0.46	-0.3	-0.13	-0.26	0.05	0.08	0.05	-0.23	0.31	-0.47	-0.33	0.42
Non Current Assets Total	0.08	-0.38	0.38	0.32	0.07	1.0	-0.12	0.02	-0.37	0.03		0.67	0.0	0.63	-0.07	-0.44	0.45	0.2	0.1	0.02	-0.38	0.34	-0.64	0.56	0.06	-0.77
Non Currrent Assets Other	0.51	-0.4	0.81	0.53	0.49	0.67	0.0	-0.24	-0.4	-0.11	0.67		0.43	0.95	0.43	-0.51	0.88	0.25	0.26	0.47	-0.44	0.59	-0.41	0.86	0.01	-0.59
Cash And Short Term Investments	0.99	-0.14	0.7	0.67	0.99	0.02	-0.09	-0.57	0.28	0.1	0.0	0.43		0.43	0.83	-0.31	0.6	0.56	0.54	1.0	0.23	0.6	0.3	0.41	0.03	0.18
Common Stock Shares Outstanding	0.51	-0.31	0.87	0.6	0.48	0.63	0.24	-0.39	-0.31	-0.33	0.63	0.95	0.43		0.54	-0.36	0.89	0.41	0.33	0.47	-0.31	0.69	-0.49	0.94	0.17	-0.63
Short Term Investments	0.84	-0.16	0.77	0.73	0.83	-0.03	0.43	-0.56	0.41	-0.46	-0.07	0.43	0.83	0.54		-0.12	0.61	0.6	0.43	0.84	0.14	0.61	0.12	0.58	0.16	-0.05
Non Current Liabilities Total	-0.33	0.57	-0.2	-0.24	-0.38	-0.4	0.45	-0.37	0.07	-0.3	-0.44	-0.51	-0.31	-0.36	-0.12		-0.3	0.27	0.09	-0.31	0.67	-0.23	-0.11	-0.34	0.8	0.01
Other Current Assets	0.67	-0.21	0.91	0.65	0.63	0.48	0.06	-0.42	-0.16	-0.13	0.45	0.88	0.6	0.89	0.61	-0.3		0.4	0.45	0.65	-0.2	0.58	-0.32	0.75	0.16	-0.46
Other Stockholder Equity	0.58	0.31	0.65	0.74	0.51	0.25	0.39	-0.91	0.25	-0.26	0.2	0.25	0.56	0.41	0.6	0.27	0.4		0.79	0.57	0.65	0.71	-0.31	0.41	0.67	-0.14
Total Liab	0.55	0.59	0.58	0.66	0.45	0.14	0.15	-0.81	0.23	0.05	0.1	0.26	0.54	0.33	0.43	0.09	0.45	0.79		0.55	0.62	0.64	-0.36	0.28	0.4	0.15
Total Current Assets	1.0	-0.14	0.73	0.69	0.99	0.05	-0.07	-0.58	0.27	0.08	0.02	0.47	1.0	0.47	0.84	-0.31	0.65	0.57	0.55		0.21	0.62	0.26	0.44	0.04	0.14
Short Term Debt	0.19	0.77	0.02	0.11	0.12	-0.35	0.2	-0.73	0.35	0.05	-0.38	-0.44	0.23	-0.31	0.14	0.67	-0.2	0.65	0.62	0.21		0.12	-0.02	-0.29	0.66	0.4
Common Stock	0.63	-0.04	0.7	0.78	0.6	0.34	0.28	-0.65	-0.15	-0.23	0.34	0.59	0.6	0.69	0.61	-0.23	0.58	0.71	0.64	0.62	0.12		-0.21	0.76	0.2	-0.16
Current Deferred Revenue	0.22	-0.32	-0.34	-0.18	0.31	-0.65	-0.37	0.26	0.23	0.31	-0.64	-0.41	0.3	-0.49	0.12	-0.11	-0.32	-0.31	-0.36	0.26	-0.02	-0.21		-0.45	-0.43	0.63
Other Assets	0.48	-0.3	0.77	0.54	0.45	0.55	0.4	-0.39	-0.33	-0.47	0.56	0.86	0.41	0.94	0.58	-0.34	0.75	0.41	0.28	0.44	-0.29	0.76	-0.45		0.15	-0.57
Long Term Debt	0.05	0.44	0.29	0.15	-0.02	0.1	0.46	-0.7	-0.08	-0.33	0.06	0.01	0.03	0.17	0.16	0.8	0.16	0.67	0.4	0.04	0.66	0.2	-0.43	0.15		-0.35
Net Receivables	0.09	0.44	-0.39	-0.21	0.1	-0.78	-0.28	-0.04	0.35	0.42	-0.77	-0.59	0.18	-0.63	-0.05	0.01	-0.46	-0.14	0.15	0.14	0.4	-0.16	0.63	-0.57	-0.35

Click cells to compare fundamentals

Larimar Therapeutics Account Relationship Matchups

Larimar Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	104.7M	78.7M	126.4M	95.9M	200.2M	210.2M
Short Long Term Debt Total	6.5M	6.0M	5.4M	5.5M	5.1M	6.9M
Other Current Liab	5.3M	6.0M	7.8M	7.4M	20.9M	21.9M
Total Current Liabilities	9.0M	8.8M	10.7M	9.5M	24.4M	12.2M
Total Stockholder Equity	89.7M	64.4M	110.9M	81.7M	171.8M	180.4M
Property Plant And Equipment Net	5.0M	4.5M	3.7M	3.8M	3.7M	2.4M
Net Debt	(61.6M)	(64.1M)	(21.4M)	(21.2M)	(28.1M)	(29.5M)
Retained Earnings	(65.6M)	(116.3M)	(151.6M)	(188.6M)	(269.2M)	(282.6M)
Accounts Payable	2.6M	1.7M	1.7M	1.3M	2.4M	2.3M
Cash	68.1M	70.1M	26.8M	26.7M	33.2M	32.2M
Non Current Assets Total	6.7M	6.5M	5.7M	5.8M	4.9M	3.3M
Non Currrent Assets Other	419K	669K	638K	659K	1.2M	1.3M
Cash And Short Term Investments	92.6M	70.1M	118.4M	86.8M	183.5M	192.6M
Common Stock Shares Outstanding	11.9M	17.2M	25.8M	43.9M	61.3M	64.3M
Short Term Investments	24.5M	0.0	91.6M	60.0M	150.2M	157.7M
Liabilities And Stockholders Equity	104.7M	78.7M	126.4M	95.9M	200.2M	210.2M
Non Current Liabilities Total	6.0M	5.4M	4.8M	4.7M	4.1M	6.8M
Other Current Assets	5.3M	1.9M	2.3M	3.4M	11.9M	12.4M
Other Stockholder Equity	155.3M	180.6M	262.5M	270.2M	440.9M	294.5M
Total Liab	15.0M	14.3M	15.5M	14.2M	28.4M	19.2M
Total Current Assets	98.0M	72.2M	120.7M	90.2M	195.3M	205.1M
Accumulated Other Comprehensive Income	1K	0.0	(31K)	81K	93.2K	97.8K
Short Term Debt	1.0M	1.2M	1.2M	837K	1.1M	1.5M
Common Stock	6K	15K	18K	43K	64K	33K
Other Assets	26K	90K	0.0	2.0M	2.3M	2.4M
Net Receivables	1.5M	158K	32K	208K	187.2K	177.8K
Capital Surpluse	444.2M	449.9M	155.3M	262.5M	236.2M	272.9M
Property Plant And Equipment Gross	5.0M	4.5M	3.7M	5.0M	5.3M	3.7M
Property Plant Equipment	361K	5.0M	4.5M	831K	955.7K	1.8M
Net Tangible Assets	(694K)	89.7M	64.4M	110.9M	127.5M	133.9M
Capital Lease Obligations	6.5M	6.0M	5.4M	5.5M	5.1M	5.3M
Net Invested Capital	89.7M	64.4M	110.9M	81.7M	171.8M	94.9M
Net Working Capital	89.0M	63.4M	110.0M	80.7M	170.9M	94.0M

Pair Trading with Larimar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Larimar Stock

0.84	CDIOW	Cardio Diagnostics	Pair Corr
0.73	ELVN	Enliven Therapeutics	Pair Corr

Moving against Larimar Stock

0.82	LUCD	Lucid Diagnostics	Pair Corr
0.75	WM	Waste Management	Pair Corr
0.63	GE	GE Aerospace	Pair Corr
0.45	PLX	Protalix Biotherapeutics	Pair Corr
0.33	PG	Procter Gamble	Pair Corr

The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.

The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Larimar Historical Balance Sheet

Larimar Therapeutics Inventory

(177,840)

About Larimar Balance Sheet Analysis

Larimar Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Larimar Therapeutics balance sheet Correlations

Larimar Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Larimar Therapeutics balance sheet Accounts

Pair Trading with Larimar Therapeutics

Moving together with Larimar Stock

Moving against Larimar Stock

Additional Tools for Larimar Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 0.96	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Total Liab	- 0.81	Retained Earnings
Net Receivables	- 0.78	Property Plant And Equipment Net
Net Receivables	- 0.77	Non Current Assets Total
Short Term Debt	- 0.73	Retained Earnings